GDTC (CytoMed Therapeutics Limited) Stock Market Reviews

crown

search

Read and share opinions on GDTC (CytoMed Therapeutics Limited) stock. Join MyTopStock.com to discover reviews, insights, and discussions from investors about this company's performance in the stock ma

GDTC

CytoMed Therapeutics Limited

clarify Biotechnology

bookmark Healthcare

public Singapore

Sell Neutral Buy

Latest News

CytoMed Therapeutics Secures Non-Dilutive Investment for Subsidiary LongevityBank from ICH Capital and Updates on New China Strategy
Nov 6, 2025
CytoMed Therapeutics’ Chairman Increases Effective Holdings to 21.95%
Oct 22, 2025
CytoMed makes cash bid for potential acquisition of TC BioPharm Limited’s relevant assets
Oct 14, 2025
CytoMed Therapeutics Announces Publication of Collaborative Research with The University of Texas, MD Anderson Cancer Center, Demonstrating the Potential of Allogeneic γδ T Cells in Acute Myeloid Leukemia
Oct 2, 2025
Update on recent acquisition - CytoMed Therapeutics expands into auto-immune diseases building on its recent cord blood bank acquisition
Aug 28, 2025
CytoMed Therapeutics Limited Announces At-the-Market (ATM) Offering Program
Aug 19, 2025
Update On Clinical Trial Milestone - CytoMed Therapeutics Achieves Completion of Dose Level 1 of its ANGELICA TRIAL, and Proceeding to Dose Level 2 in Patients with Advanced Solid Tumors or Haematological Malignancies
Jul 21, 2025
CytoMed Therapeutics Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags
Apr 30, 2025
CytoMed Therapeutics Reports Full Year Ended December 31, 2024 Financial Results and Provides Clinical and Corporate Updates
Apr 28, 2025
CytoMed Therapeutics announces Chairman’s Letter to the Company’s shareholders
Feb 6, 2025
CytoMed and SunAct Collaborate on Cancer Immunotherapy Trials in India
Jan 7, 2025
CytoMed Therapeutics signs Business & Research Collaboration Agreement with India’s SunAct Cancer Institute Private Limited to advance use of allogeneic off-the-shelf Gamma Delta T Cells for treatment of solid cancers in a proposed Phase 2 clinical trial in India
Jan 6, 2025
Update on Clinical Milestone - CytoMed Therapeutics Announces First Patient Dosed in its First-in-Human Phase I Clinical Trial of Allogeneic CAR-Gamma Delta T Cell Therapy in Patients with Advanced Solid Tumours or Haematological Malignancies
Nov 20, 2024

Reviews